Passage BIO, Inc. 8-K

What Happened
Passage Bio (PASG) filed an 8‑K on April 20, 2026 reporting updated interim data from the ongoing Phase 1/2 upliFT‑D trial of PBFT02 for frontotemporal dementia caused by progranulin deficiency (FTD‑GRN), plus regulatory and corporate updates. Key clinical findings include reduced brain atrophy and biomarker improvements at 12 months versus natural history, robust increases in CSF progranulin (PGRN) after treatment, and no new treatment‑related serious adverse events since the company’s prior update. Passage Bio also completed a Type C meeting with the FDA, which indicated a randomized controlled registrational study will be required, and the company has launched a strategic review (engaged Wedbush PacGrow) to evaluate potential transactions or other paths to maximize shareholder value.

Key Details

• Brain atrophy: PBFT02‑treated patients with baseline global CDR = 1 had average whole‑brain atrophy of 3.1% (n=2) at 12 months — a 64% reduction vs ALLFTD natural history global CDR 1 patients (n=7); frontotemporal cortex atrophy was 4.6% (n=2) at 12 months — a 54% reduction vs natural history (n=7).
• Neurofilament (NfL) and PGRN biomarkers: PBFT02 patients showed stabilization of plasma NfL with an average reduction of 1.0 pg/mL (n=6) at 12 months vs an average +13.5 pg/mL increase in untreated ALLFTD patients (n=7). Dose 1 (4.5×10^13 gc) raised CSF PGRN from <3 ng/mL at baseline to mean 22.8 ng/mL (n=6) at 12 months and 24.2 ng/mL (n=3) at 18 months; Dose 2 (2.2×10^13 gc) produced comparable CSF PGRN at 6 months (22.6 ng/mL, n=1).
• Safety and regulatory: No new treatment‑related SAEs since prior update; previously reported asymptomatic SAEs included two venous sinus thromboses and one hepatotoxicity event (Dose 1 patients). FDA stated a randomized controlled registrational trial will be required for approval in this indication.
• Corporate: Passage Bio has initiated a formal strategic review (M&A, asset sale, partnerships, etc.) and engaged Wedbush PacGrow; no assurance a transaction will occur and the company will not provide updates unless the board approves a specific action.

Why It Matters
These results show biomarker and imaging signals that could be meaningful for PBFT02’s development, but the FDA’s request for a randomized controlled registrational trial raises the cost, time and complexity of seeking approval. For investors, that increases regulatory risk and likely pushes a pivotal study timeline and budget needs higher. The initiation of a strategic review signals the company is exploring options to unlock shareholder value — which could include deals or other corporate changes — but there is no guarantee any transaction will occur. Finally, the safety profile remains under close watch given the previously reported asymptomatic SAEs.